(Q44468671)

3 December 2017

Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. (English)

1 reference

3 December 2017

1 reference

3

1 reference

3 December 2017

7

1 reference

3 December 2017

1

M A Gertz

1 reference

3 December 2017

2

M Q Lacy

1 reference

3 December 2017

5

F K Buadi

1 reference

3 December 2017

6

D Dingli

1 reference

3 December 2017

S K Kumar

4

1 reference

3 December 2017

W J Hogan

series ordinal

8

1 reference

3 December 2017

S R Hayman

series ordinal

9

1 reference

3 December 2017

language of work or name

English

0 references

publication date

11 October 2010

1 reference

Bone Marrow Transplantation

3 December 2017

1 reference

3 December 2017

46

1 reference

3 December 2017

7

1 reference

3 December 2017

970-975

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2010.234

3 December 2017

0 references

cites work

Modern treatment of amyloidosis: unresolved questions

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Transplantation for amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Immunophenotype of neoplastic plasma cells in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Autologous stem cell transplantation for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Treatment of plasma cell dyscrasias with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

7 January 2021

Managing systemic light-chain amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

7 January 2021

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

7 January 2021

Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

7 January 2021

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

7 January 2021

Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain-Associated Amyloidosis after Autologous Stem Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

7 January 2021

Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

7 January 2021

Amyloidosis and Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

7 January 2021

Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.234

7 January 2021

Identifiers

DOI

10.1038/BMT.2010.234

1 reference

release_nz5ij6mwmnhkdewlejd35j5o4i

3 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nz5ij6mwmnhkdewlejd35j5o4i

24 November 2022

mapped directly with Wikidata item

1 reference